Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Vertex Pharmaceuticals's VX-880?
VX-880 is a cell therapy commercialized by Vertex Pharmaceuticals, with a leading Phase II program in Type 1 Diabetes (Juvenile...